Next generation designer virus-like particle vaccines for dengue

Bionanotechnology for vaccine design

(2018) Steven Frey et al.   CURRENT OPINION IN BIOTECHNOLOGY

Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study

(2018) Xavier Sáez-Llorens et al.   LANCET INFECTIOUS DISEASES

Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines

(2018) Kirsten S. Vannice et al.   VACCINE

Dengue envelope-based ‘four-in-one’ virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice

(2018) Ravi Kant Rajpoot et al.   Scientific Reports

A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice

(2018) Viswanathan Ramasamy et al.   PLoS Neglected Tropical Diseases

Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo

(2018) Rahul Shukla et al.   Frontiers in Microbiology

An Envelope Domain III–based Chimeric Antigen Produced in Pichia pastoris Elicits Neutralizing Antibodies Against All Four Dengue Virus Serotypes

(2018) Behzad Etemad et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Virus-like particle vaccines: immunology and formulation for clinical translation

(2018) Braeden Donaldson et al.   Expert Review of Vaccines

Production of virus-like particles for vaccines

(2017) J. Fuenmayor et al.   New Biotechnology

Major findings and recent advances in virus–like particle (VLP)-based vaccines

(2017) Mona O. Mohsen et al.   SEMINARS IN IMMUNOLOGY

Immune correlates of protection for dengue: State of the art and research agenda

(2017) Leah C. Katzelnick et al.   VACCINE

Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial

(2017) S.B. Sirima et al.   VACCINE

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination

(2017) Stephen S. Whitehead et al.   PLoS Neglected Tropical Diseases

Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies

(2016) Niyati Khetarpal et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies

(2016) Ankur Poddar et al.   BMC BIOTECHNOLOGY

A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone

(2016) Jorge E. Osorio et al.   Expert Review of Vaccines

Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara

(2016) Mahamadou A. Thera et al.   MALARIA JOURNAL

Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort

(2016) Leah C. Katzelnick et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Status of vaccine research and development of vaccines for dengue

(2016) Kirsten S. Vannice et al.   VACCINE

Protective and immunological behavior of chimeric yellow fever dengue vaccine

(2016) Scott B. Halstead et al.   VACCINE

Engineering virus-like particles as vaccine platforms

(2016) Kathryn M Frietze et al.   Current Opinion in Virology

Recent advances in the production of recombinant subunit vaccines inPichia pastoris

(2016) Man Wang et al.   Bioengineered

Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope

(2015) Luke N. Robinson et al.   CELL

Pichia pastoris as an expression host for membrane protein structural biology

(2015) Bernadette Byrne   CURRENT OPINION IN STRUCTURAL BIOLOGY

Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates?

(2015) Jian Hang Lam et al.   Expert Review of Vaccines

Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?

(2015) Stephen S. Whitehead   Expert Review of Vaccines

Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice

(2015) Satoru Watanabe et al.   JOURNAL OF VIROLOGY

Dengue vaccine: hypotheses to understand CYD-TDV-induced protection

(2015) Bruno Guy et al.   NATURE REVIEWS MICROBIOLOGY

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

(2015) Sri Rezeki Hadinegoro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers

(2015) G. Fibriansah et al.   SCIENCE

Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host

(2015) Richard J. Kuhn et al.   VIROLOGY

Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies

(2015) Lav Tripathi et al.   Frontiers in Microbiology

Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production

(2014) Mudassar Ahmad et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?

(2014) Roslyn M. Bill   JOURNAL OF PHARMACY AND PHARMACOLOGY

A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

(2014) Wanwisa Dejnirattisai et al.   NATURE IMMUNOLOGY

Dengue Virus Neutralizing Antibody Levels Associated with Protection from Infection in Thai Cluster Studies

(2014) Darunee Buddhari et al.   PLoS Neglected Tropical Diseases

Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera

(2014) Ruklanthi de Alwis et al.   PLoS Pathogens

Pichia pastoris: protein production host and model organism for biomedical research

(2013) Brigitte Gasser et al.   Future Microbiology

The global distribution and burden of dengue

(2013) Samir Bhatt et al.   NATURE

Pichia pastoris-Expressed Dengue 2 Envelope Forms Virus-Like Particles without Pre-Membrane Protein and Induces High Titer Neutralizing Antibodies

(2013) Shailendra Mani et al.   PLoS One

Virus-like particle-based human vaccines: quality assessment based on structural and functional properties

(2013) Qinjian Zhao et al.   TRENDS IN BIOTECHNOLOGY

Virus-induced humoral immunity: on how B cell responses are initiated

(2013) Franziska Zabel et al.   Current Opinion in Virology

Dengue-specific subviral nanoparticles: design, creation and characterization

(2013) Niyati Khetarpal et al.   JOURNAL OF NANOBIOTECHNOLOGY

Antibodies against the Envelope Glycoprotein Promote Infectivity of Immature Dengue Virus Serotype 2

(2012) Júlia M. da Silva Voorham et al.   PLoS One

Humoral Immune Responses to a Single Allele PfAMA1 Vaccine in Healthy Malaria-Naïve Adults

(2012) Edmond J. Remarque et al.   PLoS One

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

(2012) R. de Alwis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development

(2012) Natasha Kushnir et al.   VACCINE

Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice

(2012) Upasana Arora et al.   VACCINE

Hepatitis E vaccine development

(2012) Ting Wu et al.   Human Vaccines & Immunotherapeutics

Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2

(2012) Upasana Arora et al.   JOURNAL OF NANOBIOTECHNOLOGY

Immune Response to Dengue Virus and Prospects for a Vaccine

(2011) Brian R. Murphy et al.   Annual Review of Immunology

The RTS,S vaccine candidate for malaria

(2011) Jason A Regules et al.   Expert Review of Vaccines

Indian vaccine innovation: the case of Shantha Biotechnics

(2011) Justin Chakma et al.   Globalization and Health

In-Depth Analysis of the Antibody Response of Individuals Exposed to Primary Dengue Virus Infection

(2011) Ruklanthi de Alwis et al.   PLoS Neglected Tropical Diseases

FDA approves kallikrein inhibitor to treat hereditary angioedema

(2010) C. A. Thompson   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

The Human Immune Response to Dengue Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing Activity

(2010) Martina Beltramello et al.   Cell Host & Microbe

Evaluation of Extracellular Subviral Particles of Dengue Virus Type 2 and Japanese Encephalitis Virus Produced by Spodoptera frugiperda Cells for Use as Vaccine and Diagnostic Antigens

(2010) M. Kuwahara et al.   Clinical and Vaccine Immunology

Correlates of Protection Induced by Vaccination

(2010) S. A. Plotkin   Clinical and Vaccine Immunology

Dengue vaccines: state of the art

(2010) Sathyamangalam Swaminathan et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Domain III of the envelope protein as a dengue vaccine target

(2010) Maria G Guzman et al.   Expert Review of Vaccines

Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes

(2010) Scott B Halstead et al.   LANCET INFECTIOUS DISEASES

Application of simple fed-batch technique to high-level secretory production of insulin precursor using Pichia pastoris with subsequent purification and conversion to human insulin

(2010) Chandrasekhar Gurramkonda et al.   Microbial Cell Factories

Immunodominant T-cell responses to dengue virus NS3 are associated with DHF

(2010) T. Duangchinda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans

(2010) W. Dejnirattisai et al.   SCIENCE

Biotechnological strains of Komagataella (Pichia) pastoris are Komagataella phaffii as determined from multigene sequence analysis

(2009) Cletus Paul Kurtzman   JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY

Dengue Virus Infections and Maternal Antibody Decay in a Prospective Birth Cohort Study of Vietnamese Infants

(2009) Tran Nguyen Bich Chau et al.   JOURNAL OF INFECTIOUS DISEASES

Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: Application to intracellular production of Hepatitis B surface antigen

(2009) Chandrasekhar Gurramkonda et al.   Microbial Cell Factories

Genome sequence of the recombinant protein production host Pichia pastoris

(2009) Kristof De Schutter et al.   NATURE BIOTECHNOLOGY

Efficient Assembly and Secretion of Recombinant Subviral Particles of the Four Dengue Serotypes Using Native prM and E Proteins

(2009) Pei-Gang Wang et al.   PLoS One

Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody

(2009) W.M.P.B. Wahala et al.   VIROLOGY

Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties

(2009) Wenquan Liu et al.   VIRUS GENES

A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model

(2009) Daniel H. Libraty et al.   PLOS MEDICINE

Pichia Power: India's Biotech Industry Puts Unconventional Yeast to Work

(2008) Chandra Shekhar   CHEMISTRY & BIOLOGY

Nanoparticles target distinct dendritic cell populations according to their size

(2008) Vania Manolova et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells

(2008) Vivian Huerta et al.   VIRUS RESEARCH